Adding metabolic agents to prostate cancer therapy: Every rose has its thorn
- PMID: 35568678
- DOI: 10.1016/j.ejca.2021.04.048
Adding metabolic agents to prostate cancer therapy: Every rose has its thorn
Conflict of interest statement
Conflict of interest statement SB: none. RM: funding for investigator-initiated research from Astellas, Bayer, Boehringer-Ingelheim, Cristal Therapeutics, Novartis, Pamgene, Pfizer, Roche, Sanofi and Servier. RdW: consultancy fees and honoraria from Sanofi-Genzyme and Merck, consultancy fees from Astellas, Janssen, Bayer and Roche, Grant support (Institution) Sanofi-Genzyme and Bayer.
Comment on
-
Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302.Eur J Cancer. 2022 Jul;170:296-304. doi: 10.1016/j.ejca.2022.03.042. Epub 2022 May 11. Eur J Cancer. 2022. PMID: 35568679 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
